Evaluation of a Photodynamic Therapy Agent Using a Canine Prostate Cancer Model

Authors

Dong Luo, Case Western Reserve UniversityFollow
Xinning Wang, Case Western Reserve UniversityFollow
Gopalakrishnan Ramamurthy, Case Western Reserve UniversityFollow
Ethan Walker, Case Western Reserve UniversityFollow
Lifang Zhang, Case Western Reserve UniversityFollow
Aditi Shirke, Case Western Reserve UniversityFollow
Naraen G. Naidu, Case Western Reserve UniversityFollow
Clemens Burda, Case Western Reserve UniversityFollow
Lee Ponsky, Case Western Reserve UniversityFollow
James Basilion, Case Western Reserve UniversityFollow

Author ORCID Identifier

James Basilion

Document Type

Article

Publication Date

5-21-2023

Abstract

Background: Male dogs can develop spontaneous prostate cancer, which is similar physiologically to human disease. Recently, Tweedle and coworkers have developed an orthotopic canine prostate model allowing implanted tumors and therapeutic agents to be tested in a more translational large animal model. We used the canine model to evaluate prostate-specific membrane antigen (PSMA)-targeted gold nanoparticles as a theranostic approach for fluorescence (FL) imaging and photodynamic therapy (PDT) of early stage prostate cancer.

Keywords

canine prostate cancer, fluorescence imaging, nanoparticles, PDT, PSMA

Publication Title

The Prostate

Rights

© 2023 The Authors. The Prostate published by Wiley Periodicals LLC.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.

Recommended Citation

Luo D, Wang X, Ramamurthy G, et al.Evaluation of a photodynamic therapy agent using a canineprostate cancer model. The Prostate. 2023;83:1176‐1185.doi:10.1002/pros.24560